
Farhad Ravandi-Kashani, MD, discusses the FDA approval of luspatercept in myelodysplastic syndrome.

Farhad Ravandi-Kashani, MD, discusses the FDA approval of luspatercept in myelodysplastic syndrome.

Farhad Ravandi, MBBS, professor of medicine, department of leukemia, The University of Texas MD Anderson Cancer Center, discusses targeting CD33 in patients with relapsed/refractory acute myeloid leukemia.

Farhad Ravandi-Kashani, MD, professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses vadastuximab talirine plus hypomethylating agents in acute myeloid leukemia.

December 12th 2018